| HOME | ABOUT | CONTACT US | PARTNERS |  |
 |
| Our Platform Technologies: | ||||||
| Antivirals | Radiation Protection | Oncology | Bio Barcode Assay | Camelidae Blood Products |
Neutraceuticals | |
|
ABOUT US Dear Shareholder, I want to firstly thank you for your interest and confidence in our developments and assure you that your investment will grow and appreciate as our Science moves forward to market. Our company is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods to patients suffering from infectious disease, cancer, and addiction. With business leadership, innovative science, exceptional people and superior products, Canopus BioPharma is committed to becoming a market trend setter in the new era of healthcare, which is focused on providing affordable therapeutic benefit and pharmaceutical excellence to patients and their carers worldwide. In addition we at Canopus BioPharma are taking a leading role with our development of novel camelid antibody products which will provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers. We at Canopus BioPharma strongly believe that the science in our pipeline will reach commercialization perpetuating the commercial success of Canopus BioPharma far into the future. It is a great moment for my team and myself, to commence upon the building of Canopus BioPharma which with our collective commitment will become a true leader in the Pharmaceutical and Biotechnology industry.
Sincerely,
Patrick T. Prendergast Chairman, Chief Executive Officer, (Director)
|
